Move to menuMove to category menuMove to main contents

SK Bioscience ESG

Our ESG Approach

Materiality Assessments

Materiality Assessment

GRI 102-15
GRI 102-47
GRI 201-1

SK bioscience has created an ESG issue pool by analyzing reporting topics from the same industry, international standards, and media. We evaluated the issues in the pool using ESG initiatives and evaluation indicators, company benchmarking, stakeholder questionnaires, and media research analysis. We selected 11 material issues based on business relevance and stakeholder interest.

<SASB Materiality Factors by Business>

<SASB Materiality Factors by Business>The main issues of SASB's business areas are in the fields of Environment, Social Capital, Human Capital, Business Model & Innovation, and Leadership & Governance.
Biotechnology & Pharmaceuticals
Environment -
Social CapitalHuman Rights & Community Relations Access & Affordability Product Quality &Safety Product Quality & Safety Customer Welfare Customer Welfare Selling Practices & Product Labeling
Human CapitalEmployee Engagement, Diversity & Inclusion
Business Model & InnovationSupply Chain Management
Leadership & GovernanceBusiness Ethics

Materiality Assessment Process

<Assessment Process>

ESG Materiality Factor

GRI 102-44

<Material Issues>

<Material Issues>The important issues are divided into the areas of Economy, Environment, Social, and Governance.
CategoryMaterial issues
Economy
  • Future growth strategies
Environment
  • Minimization of environmental impact
  • Response to climate change
Social
  • Product safety and quality
  • Talent acquisition and development
  • Creating SV (social value) through business
  • Expansion of human rights management
  • Expansion of corporate philanthropy activities and community participation
Governance
  • Advancement of ethical/compliance management
  • Reinforcement of Board-led management
  • ESG management internalization